- Trial phase
- Approved
- Time to market
- Already approved and commercially launched (January 30, 2025)
- Why 4/10
- AXS-07 (SYMBRAVO) is already FDA-approved (January 30, 2025) and commercially launched, there is no pending PDUFA, pivotal readout, or hard binary catalyst for this specific drug in the next ~12 months. The impact score reflects that it is an approved product in early commercial ramp, making up a small portion ($4.1M Q1 revenue) of a multi-product company where bigger catalysts (AUVELITY Alzheimer's agitation launch, pipeline readouts) dominate the thesis.
AXS-07 is already approved and generating early revenue, so its binary risk is behind it. For an AXSM investor, watch SYMBRAVO prescription trends and payer access as leading indicators of commercial traction, but the bigger near-term stock drivers are AUVELITY's Alzheimer's agitation launch and pipeline catalysts for AXS-12/solriamfetol.
Price Chart
Executive Summary
AXS-07 (brand name SYMBRAVO) is an FDA-approved oral migraine medication from Axsome Therapeutics combining meloxicam (NSAID) and rizatriptan (triptan) using MoSEIC rapid-absorption technology. It was approved January 30, 2025 for acute migraine in adults after positive Phase 3 data. Early commercial launch generated $4.1M in Q1 2026 revenue. The drug is now a marketed product rather than a binary catalyst, its approval risk is resolved, and commercial execution is the watchpoint. AXS-07 is one of three commercial products at Axsome, where AUVELITY ($153M quarterly revenue) is the dominant value driver.
How It Works
AXS-07 is a two-drug combination pill for migraine. One component (meloxicam) is an NSAID that reduces inflammation and blocks CGRP (a protein involved in migraine pain). The other (rizatriptan) is a triptan that constricts dilated blood vessels in the brain and blocks pain signals. The MoSEIC technology makes both drugs absorb faster, giving quicker relief.
Trial Status
Phase 3 MOMENTUM and INTERCEPT trials met co-primary and key secondary endpoints. The EMERGE open-label Phase 3 trial in CGRP-inadequate responders is completed. Pooled Phase 3 analyses published April 2024 showed efficacy on pain freedom, most bothersome symptoms, and reduced rescue medication use. FDA approved January 30, 2025 following a CRL in May 2022 (CMC issues, since resolved).
The Two-Sided Case
Upcoming Catalysts
- SYMBRAVO prescription and revenue trajectory in upcoming quarterly earnings reports
- Potential payer/formulary coverage decisions and market access milestones
- New SYMBRAVO data presentations at medical conferences (e.g., AHS 2026 data presented June 2026)
- Possible label expansion or pediatric study initiation (no formal catalyst announced yet)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Axsome Therapeutics, Inc. COURT-RULING AXSM ·Originating report